rifaximin (Xifaxan, Fatroximin, Normix)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Xifaxam

Indications

Dosage

Tabs: 200 mg, 550 mg

Pharmacokinetics

Adverse effects

Drug interactions

Mechanism of action

Notes

More general terms

References

  1. 1.0 1.1 Prescriber's Letter 11(7):38 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=200706&pb=PRL (subscription needed) http://www.prescribersletter.com
  2. 2.0 2.1 Journal Watch 25(13):103, 2005 DuPont HL, Jiang ZD, Okhuysen PC, Ericsson CD, de la Cabada FJ, Ke S, DuPont MW, Martinez-Sandoval F. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med. 2005 May 17;142(10):805-12. Summary for patients in: Ann Intern Med. 2005 May 17;142(10):I30. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15897530
  3. 3.0 3.1 Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med. 2006 Oct 17;145(8):557-63. Summary for patients in: Ann Intern Med. 2006,145(8):I24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17043337
    Drossman DA. Treatment for bacterial overgrowth in the irritable bowel syndrome. Ann Intern Med. 2006 Oct 17;145(8):626-8. (No abstract) PMID: https://www.ncbi.nlm.nih.gov/pubmed/17043344
  4. 4.0 4.1 FDA NEWS RELEASE, March 24, 2010 FDA Approves New Use of Xifaxan for Patients with Liver Disease http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm206104.htm
    Bass NM, Mullen KD, Sanyal A et al Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Mar 25;362(12):1071-81 PMID: https://www.ncbi.nlm.nih.gov/pubmed/20335583
  5. 5.0 5.1 Prescriber's Letter 17(6): 2010 Rifaximin (Xifaxan) for Hepatic Encephalopathy Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=260608&pb=PRL (subscription needed) http://www.prescribersletter.com
    Sidhu SS et al. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (The RIME Trial). Am J Gastroenterol 2011 Feb; 106:307. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21157444
    Bajaj JS et al. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. Gastroenterology 2011 Feb; 140:478. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20849805
  6. 6.0 6.1 6.2 Pimentel M et al Rifaximin Therapy for Patients with Irritable Bowel Syndrome without Constipation N Engl J Med. 2011 Jan 6;364(1):22-32. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21208106 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1004409
    Tack J Antibiotic Therapy for the Irritable Bowel Syndrome N Engl J Med. 2011 Jan 6;364(1):81-2. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/21208112 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1011211
  7. 7.0 7.1 FDA News Release. May 27, 2015 FDA approves two therapies to treat IBS-D http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm448328.htm
  8. NEJM Knowledge+ Gastroenterology
  9. 9.0 9.1 9.2 9.3 HIGHLIGHTS OF PRESCRIBING INFORMATION XIFAXAN<TM> (rifaximin) tablets, for oral use https://shared.salix.com/globalassets/pi/xifaxan550-pi.pdf

Database